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IP drag
CIRM president Alan Trounson described the route through which multiple technologies result in a few therapies: technologies must be patentable so that investors can get a return on their investment, he said, but IP can also clog the pipeline. "Biotech companies come and they go, and their IP gets stuck," he said. "We need agreements in place that don't block the pipeline."
What shape those agreements might take was unclear. Alan Bennett of the University of California, Davis described the IP-pooling agency he directs. The Public Intellectual Property Resource for Agriculture (PIPRA), based at UC Davis, was formed when a bunch of agricultural colleges came together as a one-stop shop to license the complementary pieces of IP necessary for engineering new crops and other products. Revenues generated by the licenses are shared according to a preagreed formula among the universities. The audience seemed both highly interested in this as a potential model and highly sceptical. One difficulty in transferring the idea to stem cells is that biomedical science anticipates higher revenues and, so, higher stakes. Also, PIPRA got started under the aegis of the philanthropic Rockefeller Foundation. Even so, Bennett said it took about two years of meeting with high-level university administrators and tech transfer officers before cooperation could get underway.
Sean O'Conner, a professor at the University of Washington School of Law, in Seattle, proposed that patent enforcement similar to that practiced in Japan and South Korea could make technologies more accessible. In those countries, a patented technology can be used freely for research and development (R&D). Only when that R&D yields a product that could produce revenues are the patents considered. 
Scientific data flow
Getting a notion of what patents exist could be a precursor to combining patents in productive ways and clearing the 'patent thicket' in which researchers don't develop products because necessary steps are blocked by IP claims.
Another hindrance is that scientists aren't always sure what they should expect from different cell lines grown under different conditions. "We need a database with all the molecular markers and how they change in a culture dish," said Mike West, founder of Geron and former president of Advanced Cell Technology Inc., in Los Angeles. "I don't know how the field can progress without the map."
Scientists argue broadly for sharing resources, but there are
We need someone to mobilize the effort to map the human embryo. I don't know how the field can progress without the map.
Michael West Founder of Geron Corp.
Scientists argue broadly for sharing resources, but there are powerful disincentives not to do so, said Pam Samuelson, a professor at the Boalt School of Law at University of California, Berkeley. Sharing data can dissipate the rewards gained from the hard work of data collection and can jeopardize trade secrets. Scrubbing and formatting data so it can be shared without violating subjects' privacy takes considerable time. "There's no reward for doing it, and no penalty for not doing it," she said. The first scientists to share data have little to gain, and those with the biggest data sets have the most to lose. Similar constraints exist in sharing research materials.
Samuelson and participants discussed several strategies to promote data sharing. Default standards would make reformatting easier. But there should also be a system of carrots and sticks. People who share useful data or materials should be rewarded; perhaps the number of times a dataset is downloaded could be tracked and acknowledged. Researchers who don't share should be excluded from future grant applications or using other resources.
Scientists cannot rely on getting the data or materials they need from other researchers, and resources are squandered when scientists duplicate efforts, said Jeanne Loring, of The Scripps Research Institute, in La Jolla, California, and Jon Auerbach, CEO of GlobalStem Inc., in Rockville, Maryland, and chair of the standards committee for the International Society for Stem Cell Research, based in Northbrook, Illinois. The research community needs a system of repositories that can supply cell lines. "One bank in the UK and one bank in Wisconsin isn't enough," said Auerbach. "But you don't need a bank in every state or institution."
The solutions, they said, are registries, repositories, databases and common standards for supplying information and other resources. Ideally, a registry for scientists would describe genomic stability over time, cell lines' differentiation tendencies and marker expressions, and the tests used for assessing particular lines. However, if researchers are to trust such data, stakeholders must agree on definitions, methodologies, protocols and reference standards. Ideally, the same factors would be measured across multiple cell lines in multiple labs, but such efforts are difficult because of differences in funding.
